,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['bcsm', 'destiny,breast,4', 'breast', 'destiny-breast04']
"a beautiful, powerful moment, that will remain in the history of breast oncology," says of the standing ovation after the #asco22 plenary presentation of destiny-breast04 by shanu modi, md, of . #bcsm 
OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals.